ID: ALA301605

Max Phase: Preclinical

Molecular Formula: C17H11N3

Molecular Weight: 257.30

Molecule Type: Small molecule

Representations

Canonical SMILES:  c1ccc2c(c1)[nH]c1c2ncc2[nH]c3ccccc3c21

Standard InChI:  InChI=1S/C17H11N3/c1-3-7-12-10(5-1)15-14(19-12)9-18-16-11-6-2-4-8-13(11)20-17(15)16/h1-9,19-20H

Standard InChI Key:  UFTKNTUWDMJOIX-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 257.30

Molecular Weight (Monoisotopic): 257.0953

AlogP: 4.35

#Rotatable Bonds: 0

Polar Surface Area: 44.47

Molecular Species: NEUTRAL

HBA: 1

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 3

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 12.45

CX Basic pKa: 2.87

CX LogP: 3.38

CX LogD: 3.38

Aromatic Rings: 5

Heavy Atoms: 20

QED Weighted: 0.43

Np Likeness Score: 0.18

References

1. Allen MS, Hagen TJ, Trudell ML, Codding PW, Skolnick P, Cook JM..  (1988)  Synthesis of novel 3-substituted beta-carbolines as benzodiazepine receptor ligands: probing the benzodiazepine receptor pharmacophore.,  31  (9): [PMID:2842507] [10.1021/jm00117a029]

2. Silverman BD, Platt DE..  (1996)  Comparative molecular moment analysis (CoMMA): 3D-QSAR without molecular superposition.,  39  (11): [PMID:8667357] [10.1021/jm950589q]

3. Allen MS, Tan YC, Trudell ML, Narayanan K, Schindler LR, Martin MJ, Schultz C, Hagen TJ, Koehler KF, Codding PW..  (1990)  Synthetic and computer-assisted analyses of the pharmacophore for the benzodiazepine receptor inverse agonist site.,  33  (9): [PMID:2167977] [10.1021/jm00171a007]

4. Trudell ML, Lifer SL, Tan YC, Martin MJ, Deng L, Skolnick P, Cook JM..  (1990)  Synthesis of substituted 7,12-dihydropyrido[3,2-b:5,4-b']diindoles: rigid planar benzodiazepine receptor ligands with inverse agonist/antagonist properties.,  33  (9): [PMID:2167978] [10.1021/jm00171a015]

5. Good AC, Peterson SJ, Richards WG..  (1993)  QSAR's from similarity matrices. Technique validation and application in the comparison of different similarity evaluation methods.,  36  (20): [PMID:8411009] [10.1021/jm00072a012]

6. Allen MS, Skolnick P, Cook JM..  (1992)  Synthesis of novel 2-phenyl-2H-pyrazolo[4,3-c]isoquinolin-3-ols: topological comparisons with analogues of 2-phenyl-2,5-dihydropyrazolo[4,3-c]quinolin-3(3H)-ones at benzodiazepine receptors.,  35  (2): [PMID:1310121] [10.1021/jm00080a024]

7. So SS, Karplus M..  (1997)  Three-dimensional quantitative structure-activity relationships from molecular similarity matrices and genetic neural networks. 2. Applications.,  40  (26): [PMID:9435905] [10.1021/jm970488n]

8. Trudell ML, Basile AS, Shannon HE, Skolnick P, Cook JM..  (1987)  Synthesis of 7,12-dihydropyrido[3,4-b:5,4-b']diindoles. A novel class of rigid, planar benzodiazepine receptor ligands.,  30  (3): [PMID:3029372] [10.1021/jm00386a003]

9. Huang Q, He X, Ma C, Liu R, Yu S, Dayer CA, Wenger GR, McKernan R, Cook JM..  (2000)  Pharmacophore/receptor models for GABA(A)/BzR subtypes (alpha1beta3gamma2, alpha5beta3gamma2, and alpha6beta3gamma2) via a comprehensive ligand-mapping approach.,  43  (1): [PMID:10633039] [10.1021/jm990341r]

10. Xia B, Ma W, Zheng B, Zhang X, Fan B..  (2008)  Quantitative structure-activity relationship studies of a series of non-benzodiazepine structural ligands binding to benzodiazepine receptor.,  43  (7): [PMID:17964693] [10.1016/j.ejmech.2007.09.004]

11. Beato A, Gori A, Boucherle B, Peuchmaur M, Haudecoeur R..  (2021)  β-Carboline as a Privileged Scaffold for Multitarget Strategies in Alzheimer's Disease Therapy.,  64  (3.0): [PMID:33528252] [10.1021/acs.jmedchem.0c01887]

Source

Source(1):

• Scientific Literature